Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This study was designed to investigate the response of Type III hyperlipoproteinemic subjects to bezafibrate therapy. The metabolism of apolipoprotein B was examined in four lipoprotein subclasses of Sf 60-400 (large very low density lipoprotein (VLDL)), Sf 20-60 (small VLDL), Sf 12-20 (intermediate density lipoprotein (IDL)), and Sf 0-12 (low density lipoprotein (LDL)) before and during bezafibrate therapy. Treatment reduced the plasma concentration of VLDL and raised high density lipoprotein (HDL) cholesterol. There was no net change in LDL cholesterol or its associated apolipoprotein B. The decrease in plasma VLDL derived mainly from an inhibition of synthesis of both large and small subfractions which reduced the number of particles in the circulation without normalizing their lipid composition. Catabolism of the larger VLDL also increased, presumably as a result of lipoprotein lipase activation. Although the plasma concentration of LDL was unchanged, both its synthesis and catabolism were perturbed. Its fractional catabolic rate fell by 50%, but the impact that this would have had on its steady state level in the circulation was apparently blunted by a decrease in its synthesis from Sf 12-20 IDL. In the control phase of the study, most IDL apolipoprotein B was converted to LDL. Bezafibrate therapy channelled this material towards direct catabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man
UTERMANN, G., HEES, M., & STEINMETZ, A. (1977) · Nature · doi:10.1038/269604a0 · Cited by 666
Utermann, G., Jaeschke, M., & Menzel, J. (1975) · FEBS Letters · doi:10.1016/0014-5793(75)81125-2 · Cited by 337
The biochemical, clinical, and genetic features of type III hyperlipoproteinemia.
MORGANROTH, J., LEVY, R. I., & FREDRICKSON, D. S. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-158 · Cited by 260
Cited by
Lipoprotein Heterogeneity and Apolipoprotein B Metabolism
Packard, C. J., & Shepherd, J. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3542 · Cited by 402
Self-citationWatts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Demant, T., Bedford, D., Packard, C. J., & Shepherd, J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115459 · Cited by 145
Self-citationChanges in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives
Ginsberg, H. N. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90873-4 · Cited by 32
Metadata
- Authors
- Packard, C. J., Clegg, R. J., Dominiczak, M. H., Lorimer, A. R., & Shepherd, J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 1990-04
- Volume
- 27
- Issue
- 9
- Pages
- 930-938
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2144198808
- Cited by
- 54
- References
- 4
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. https://app.cochat.ai/papers/10.1016/s0022-2275(20)38775-7
- The paper
- Packard, C. J., Clegg, R. J., Dominiczak, M. H., Lorimer, A. R., & Shepherd, J. (1990). Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. Journal of Lipid Research. https://doi.org/10.1016/s0022-2275(20)38775-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.